James Wilbeck, MD
Nephrology · Franklin, TNNPI 1548317498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 32.9% of the total.
Across 69 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$541
- Fresenius USA Marketing, Inc.$362
- Nxstage Medical, Inc.$160
- Otsuka America Pharmaceutical, Inc.$131
- Travere Therapeutics, Inc.$104
- Ardelyx, Inc.$94
- plus $249 from 6 others
Across 296 payments — averaging $376.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$109K
- Ironwood Pharmaceuticals, Inc$2K
What the payments were for
- Food & beverage$1,57096%
- Education$724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $541 |
| Fresenius USA Marketing, Inc. | 20 | $362 |
| Nxstage Medical, Inc. | 3 | $160 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Travere Therapeutics, Inc. | 15 | $104 |
| Ardelyx, Inc. | 4 | $94 |
| Novartis | 3 | $72 |
| Boehringer Ingelheim | 3 | $61 |
| Akebia Therapeutics Inc | 2 | $44 |
| Calliditas Therapeutics US Inc. | 1 | $40 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,642 in reported general payments places this provider in the 55th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 31 | $119,723 |
| FarxigaDapagliflozin Propanediol | 189 | $115,148 |
| AuryxiaFerric Citrate | 25 | $49,733 |
| VeltassaPatiromer Calcium Sorbitex | 40 | $34,840 |
| JardianceEmpagliflozin | 47 | $32,059 |
| Sevelamer Carbonate | 61 | $6,546 |
| Calcium Acetate | 32 | $4,636 |
| Potassium Citrate ErPotassium Citrate | 35 | $4,206 |
| Mycophenolate Mofetil | 14 | $1,897 |
| Nifedipine ErNifedipine | 66 | $1,825 |
| Torsemide | 44 | $1,420 |
| Losartan Potassium | 121 | $1,180 |
| Potassium Chloride | 40 | $1,070 |
| Furosemide | 158 | $866 |
| Tamsulosin Hcl | 71 | $820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $362 | $119,72331 claims |
| AstraZenecaFarxiga | $541 | $115,148189 claims |
| Akebia Therapeutics IncAuryxia | $44 | $49,73325 claims |
| Boehringer IngelheimJardiance | $61 | $32,05947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Franklin
- Jamie DwyerNashville$461K
- Ross NesbitKnoxville$452K
- Gerald BorrelliKnoxville$190K
- Volker HaaseNashville$123K
- Chike NzerueCookeville$95K
- Talat IkizlerNashville$93K
- Omar HamzeMemphis$90K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Omar DavisMemphis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.